Electromed, Inc. Hits New 52-Week High of $39.20, Up 453%

Electromed, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 39.20 on May 22, 2026. This achievement marks a remarkable 453.11% increase in the stock's performance over the past year, significantly outpacing the S&P 500's performance of 27.93% during the same period. With a market capitalization of USD 197 million, Electromed operates within a competitive industry landscape. The company's price-to-earnings (P/E) ratio stands at 22.00, indicating its valuation relative to earnings. Additionally, Electromed's return on equity is reported at 20.11%, reflecting its efficiency in generating profits from shareholders' equity. The stock's price-to-book ratio is noted at 4.33, providing insight into its market valuation compared to its book value. Electromed's journey to this new high is underscored by its strong performance metrics, showcasing its position in the market and the overall growth trajectory it has experienced over the past year.